Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
AI Technology | 28/01/2026 | By News Bureau
Agilent Technologies, Lunit Partner to Develop AI-Powered Companion Diagnostic Tools
Agilent Technologies has entered into a nonexclusive collaboration with Korea-based Lunit to develop AI-based companion diagnostic solutions.
AI Technology | 23/09/2025 | By Dineshwori | 219
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy